Nexvet expands veterinary biologics research team
Nexvet Biopharma has added two former CSL (ASX:CSL) scientists to its veterinary biologics research team.
CSL’s former director of preclinical cell biology, Dr Samantha Busfield, and former director of analytical biochemistry, Dr Dallas Hartman, have both joined Nexvet’s veterinary biologics research centre in Melbourne.
The centre is designed to bolster Nexvet’s product pipelines and support the company’s existing veterinary drug programs. Nexvet specialises in species-specific biologic treatments for companion animals, produced with its PETization platform.
“I’m delighted to welcome two such experienced research managers to the Nexvet team,” Nexvet chief science officer Dr David Gearing commented. “Their breadth of experience in research and development in biopharmaceuticals will be invaluable.”
He said Nexvet is putting together a team of scientists with diverse biopharma backgrounds for its research activities.
“We are excited about our work on new animal therapies, building on our pioneering research in this field to build a world-class centre for veterinary biologics research,” Gearing said.
In April, Nexvet raised US$31.5 million ($34.9 million) to fund clinical programs for treatment candidates for canine pain, feline pain and canine inflammation.
3D-printed films provide targeted liver cancer treatment
Researchers have created drug-loaded, 3D-printed films that kill more than 80% of liver cancer...
Using your brain at work may ward off cognitive impairment
The harder your brain works at your job, the less likely you may be to have memory and thinking...
Repurposed drugs show promise in heart muscle regeneration
The FDA-approved medications, when given in combination, target two proteins that regulate the...
